Related Experiment Video

Updated: May 23, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:53

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

799

Anti-inflammatory effects and gut microbiota modulation of synbiotic mulberry in DSS-induced colitis rats

Atcharaporn Ontawong1, Arthid Thim-Uam2, Sirinat Pengnet1

  • 1Division of Physiology, School of Medical Sciences, University of Phayao, Phayao, 56000, Thailand.

Molecular and Cellular Biochemistry
|May 21, 2025
PubMed

Insights

Synbiotic mulberry (SM) effectively reduced inflammation and improved gut health in rats with colitis. This functional food shows promise for treating inflammatory bowel disease (IBD), warranting further clinical investigation.

Area of Science:

  • Gastroenterology
  • Microbiology
  • Nutrition Science

Background:

  • Inflammatory bowel disease (IBD) cases surged by 88.30% in 2021, impacting patient quality of life.
  • Synbiotics offer a potential therapeutic avenue for IBD management.
  • The anti-inflammatory effects and gut microbiota modulation of synbiotic mulberry (SM) in colitis models require further exploration.

Purpose of the Study:

  • To investigate the anti-inflammatory activity of synbiotic mulberry (SM) in dextran-sodium-sulfate (DSS)-induced colitis rats.
  • To analyze the impact of SM on gut microbiota composition in a colitis model.
  • To evaluate SM as a potential functional food therapeutic for colitis.

Main Methods:

  • Rats were induced with acute colitis using DSS and divided into seven groups, including control, DSS, DSS+SM (varying doses), and DSS+Sulfazalazine (SUL).
  • Treatments were administered daily via oral gavage for 14 days.
  • Disease activity index (DAI), body weight (BW), organomegaly, colon length, colon histomorphology, and gut microbiota composition were assessed.

Main Results:

  • SM administration significantly improved DAI, BW, hepatosplenomegaly, colon length, and colon histomorphology, comparable to SUL.
  • SM treatment reduced IL-6 levels and suppressed iNOS and IL-10 mRNA expression in the colon.
  • SM significantly modulated gut microbiota, increasing the abundance of Allobaculum and affecting metabolic enzyme classes.

Conclusions:

  • Synbiotic mulberry (SM) demonstrates significant anti-inflammatory effects and improves gut health in DSS-induced colitis rats.
  • SM may serve as a promising functional food therapeutic for colitis.
  • Further clinical trials are necessary to validate the therapeutic potential of SM for inflammatory bowel disease.
Keywords:
Dextran-sodium-sulfateGut microbiotaInflammatory bowel diseasePro-inflammatory cytokineSynbiotic mulberry

More Related Videos

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.2K
DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat09:04

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

47.2K

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
115
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
133
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
124
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
290
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
84
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
213